Business
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference
Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including increased relative
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including increased relative proportion of Actinobacteria in ibezapolstat-treated patients with C. difficile Infection (CDI)Results consistent with those shown in earlier human volunteer studies and Phase 2a studiesPreservation and increased concentrations of beneficial Firmicute (Bacilotta) phylum known to be involved in bile acid homeostasis and short chain fatty acid metabolism was demonstrated Actinobacteria and Bacteroides preservation also confirmed using quantitative analysisSTATEN ISLAND, N.Y., July 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat (IBZ) Phase 2 clinical trial in patients with C. difficile Infection (CDI) were presented at the 17th Biennial Congress of the Anaerobe Society of the Americas on July 11th which was held at the University of Michigan, Ann Arbor, from July 8 to 11, 2024. Taryn A. Eubank, PharmD, BCIDP, Research Assistant Professor, University of Houston College of Pharmacy delivered an oral presentation entitled: \"Clinical Efficacy of Ibezapolstat in CDI: Results from Phase 2 trials.\"\n\nCommenting on Dr. Eubank's presentation, Kevin Garey, PharmD, MS, FIDSA, Professor and Chair, University of Houston College of Pharmacy, Principal Investigator for microbiology and microbiome aspects of the ibezapolstat clinical trial program, and Acurx Scientific Advisory Board member, stated:\"The ibezapolstat clinical development plan has included the most robust microbiome development plan ever undertaken with prior analyses predicting an anti-recurrence effect of ibezapolstat in patients with CDI.\" Dr. Garey further added: \"Microbiome results from the Phase 2b trial are helping to validate this approach as a consistent anti-recurrence effect has been seen along with the microbiome effect explaining the underlying mechanism of action. I would anticipate that these analyses will set a new standard for CDI-directed antibiotics and perhaps for antibiotic development, in general.\"\nRobert J. DeLuccia, Executive Chairman of Acurx, stated: \"Ibezapolstat continues to demonstrate favorable effects ...